In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Artisan Pharma gets rights to Asahi Kasei Pharma's ART123

Executive Summary

Concurrent with the closing of its $39mm Series A venture round, newly formed Artisan Pharma (in-licensing late-stage drug candidates or already-marketed therapeutics and developing them for unmet medical needs) has licensed worldwide development and marketing rights to Asahi Kasei Pharma's (AKP; develops pharmaceuticals, diagnostics, and medical devices) ART123. The license excludes Japan, China, Taiwan, and Korea, where AKP is keeping rights.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies